Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 78

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 78
---
-based particles, our approach is
intended to enable controlled release, improve biodistribution to diseased tissues, and extend systemic circulation time. These pharmacokinetic
and pharmacodynamic enhancements may collectively improve the therapeutic index by increasing efficacy at the site of disease while potentially
reducing systemic exposure and associated toxicities. Planned clinical trials are designed to evaluate whether this approach can expand
treatment options for conditions with significant unmet medical need, including antimicrobial resistance and solid tumor.

Our core business strategy combines disciplined
product candidate development with strategic deployment of internal expertise and effective use of external resources. We leverage our
experienced executive management team and our established networks throughout the biopharmaceutical industry to identify and develop
product candidates that we believe can provide superior clinical benefits to patients living with life-threatening conditions.

Nanoparticle-based therapies involve using
tiny particles (nanoparticles) to deliver drugs or other therapeutic agents to specific locations in the body, often with the goal of
enhancing treatment effectiveness and minimizing side effects. These nanoparticles, typically ranging from 1 to 1000 nanometers
in size, can be engineered to encapsulate various therapeutic agents, including proteins, nucleic acids, or small molecule drugs. Compared
to conventional drugs, nanoparticle-based drug delivery has specific advantages, such as improved stability and biocompatibility, enhanced
permeability and retention effect, and improved targeting to diseased tissues such as tumors or sites of infection.

While the abovementioned attributes have been
observed in preclinical models, there can be no assurance that they will be replicated in clinical studies or translate into meaningful
patient outcomes. Our product candidates are in early stages of development and have not yet been clinically tested in the United States
or elsewhere.

<div align='center'>47

Technology and Industry Overview</div>

Market Opportunities

Nanoparticles-based therapies, also referred
to as nanomedicines or nano delivery systems, are employed to serve as means of diagnostic tools or to deliver therapeutic agents to
specific targeted sites in a controlled manner. Nanotechnology offers multiple benefits in treating chronic human diseases by site-specific,
and target-oriented delivery of precise medicines. These systems enable site-specific, controlled delivery of pharmaceutical agents,
including chemotherapeutic, biological, and immunotherapeutic compounds, with what we believe to be improved safety and efficacy profiles.

Liposomal and lipid-based nanoparticles are
designed to improve the therapeutic index of both novel and existing drugs by modifying pharmacokinetics, enhancing absorption, reducing
met